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Abstract  55 
Background & Aims 56 
Patients with autoimmune hepatitis (AIH) commonly receive induction therapy with 57 
predniso(lo)ne followed by maintenance therapy with azathioprine. European 58 
Association for Study of the Liver clinical practice guidelines advise a predniso(lo)ne 59 
dose range of 0.50–1 mg/kg/day, which leaves room for practice variation. We 60 
performed a multicenter study to determine the efficacy of different dose ranges of 61 
predniso(lo)ne induction therapy in a large European cohort of patients with AIH. 62 
Methods 63 
We performed a retrospective cohort study using a comparative effectiveness design. 64 
We collected data from 451 adults with AIH who began treatment from 1978 through 65 
2017 at 9 centers in 5 European countries. We assigned patients to a high-dose 66 
group (initial predniso(lo)ne dose ≥0.50 mg/kg/day; n=281) or a low-dose group 67 
(<0.50 mg/kg/day; n=170). Logistic regression was performed to determine difference 68 
in outcomes between the groups. The primary outcome was normal serum levels of 69 
transaminases at 6 months after initiation of therapy. 70 
Results 71 
There was no significant difference in rates of normalization of transaminases 72 
between the high-dose predniso(lo)ne group and the low-dose group (70.5% vs 73 
64.7%; P=.20). After multivariable logistic regression with correction for confounders, 74 
there was no difference in the likelihood of normalization of transaminases between 75 
the groups (odds ratio, 1.21; 95% CI, 0.78 – 1.87; P=.38). Patients given an initial 76 
high dose of predniso(lo)ne received more predniso(lo)ne over time than patients 77 
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started on a lower dose (median doses over 6 months: 3780 mg vs 2573 mg) 78 
(P<.01). 79 
Conclusions 80 
In a retrospective study of patients with AIH in Europe, we found that the dose of 81 
predniso(lo)ne to induce remission in patients with AIH is less relevant than 82 
assumed. An initial predniso(lo)ne dose below 0.50 mg/kg/day substantially 83 
decreases unnecessary exposure to predniso(lo)ne in patients with AIH. 84 
Keywords 85 
EASL guidelines, ALT, AST, IgG, corticosteroid, induction therapy, cirrhosis, 86 
prednisone, prednisolone. 87 
88 
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LIST OF ABBREVATIONS 89 
AASLD  American Association for the Study of Liver Diseases 90 
ALT   Alanine aminotransferase 91 
AST   Aspartate aminotransferase 92 
ANA   Anti-nuclear antibody 93 
AIH   Autoimmune hepatitis 94 
CI   Confidence interval 95 
EASL   European Association for the Study of the Liver 96 
IAIHG   International Autoimmune Hepatitis Group 97 
IgG   Immunoglobulin G 98 
INR   International normalized ratio 99 
IRB   Institutional Review Board 100 
LKM1   Liver kidney microsome type 1 101 
OR   Odds ratio 102 
PBC   Primary biliary cholangitis 103 
PSC   Primary sclerosing cholangitis 104 
SMA   Smooth muscle antibody 105 
SLA/LP  Soluble liver antigen / liver pancreas 106 
ULN   Upper limit of normal  107 
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INTRODUCTION 108 
Autoimmune hepatitis (AIH) is a rare, chronic liver disease characterized by 109 
inflammatory liver histology, circulating autoantibodies and increased serum levels of 110 
immunoglobulin G (IgG). The etiology of AIH is elusive but there is a clear genetic 111 
susceptibility 1. When left untreated, AIH may progress to cirrhosis and end-stage 112 
liver disease 2. Therapy, immunosuppressive by nature, is aimed at inducing and 113 
maintaining remission of disease and prevention of fibrosis progression. Biochemical 114 
remission, which is defined as normalization of both serum transaminases and serum 115 
IgG has been accepted as a surrogate endpoint for treatment 3.  116 
Current therapy for AIH consists of prednisone/prednisolone monotherapy or a 117 
combination therapy of predniso(lo)ne and azathioprine. The supporting evidence 118 
comes from clinical trials performed in the 1970s and 1980s 4-9. These studies 119 
established the role of predniso(lo)ne in AIH but fail to provide data on its therapeutic 120 
window. Predicting the response to predniso(lo)ne treatment is relevant, particularly 121 
in AIH, because attenuation of hepatic inflammation reduces the risk of liver related 122 
complications in patients with and without cirrhosis 6-8, 10, 11. However, the role of 123 
predniso(lo)ne in patients presenting with acute severe AIH (AS-AIH) is not fully 124 
elucidated 12-14. Regarding the predniso(lo)ne at start of therapy, guidelines provide 125 
conflicting recommendations. The American Association for the Study of Liver 126 
Diseases (AASLD) and British Society of Gastroenterology (BSG) advise 30 mg/day 127 
in combination with azathioprine, which corresponds to 0.50 mg/kg/day in a 60 kg 128 
patient 15 16. In contrast, the most recent guideline, the European Association for 129 
Study of the Liver (EASL) Clinical Practice Guideline suggests a predniso(lo)ne 130 
starting dose in a range from 0.50 – 1 mg/kg/day 3. Furthermore, data on 131 
predniso(lo)ne starting dosages in patients with cirrhosis at presentation, are lacking. 132 
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In view of these divergent recommendations, practice variation among 133 
physicians and centers may arise when it comes to predniso(lo)ne dosages used for 134 
AIH induction therapy. Indeed, in a recent International Autoimmune Hepatitis Group 135 
(IAIHG) survey among AIH experts, participants reported a dose ranging from 20 to 136 
100 mg/day when asked for the optimal starting dose for a hypothetical 75 kg patient 137 
with acute AIH 17, 18. The lowest effective dose of predniso(lo)ne in AIH and 138 
information on a dose-effect relation between predniso(lo)ne and achieved 139 
biochemical remission are unclear. Therefore, we established a cohort with AIH 140 
patients derived from multiple international centers to compare the efficacy of a high- 141 
versus a low-dose predniso(lo)ne induction therapy on biochemical endpoints and 142 
steroid-related side effects.  143 
METHODS 144 
Study design 145 
We performed a retrospective cohort study using a comparative effectiveness 146 
design. We analyzed AIH patients from nine different centers across five European 147 
countries in Europe. Treatment was initiated between 1978 and 2017. Inclusion 148 
criteria were a new diagnosis of probable or definite AIH using clinical, biochemical, 149 
serological and histopathological results consistent with the simplified or revised 150 
IAIHG criteria 19, 20, age ≥18 years at time of diagnosis and induction therapy with 151 
predniso(lo)ne. Patients were excluded if they had overlapping features of primary 152 
biliary cholangitis (PBC) or primary sclerosing cholangitis (PSC), suffered from other 153 
liver diseases (e.g. viral hepatitis or non-alcoholic fatty liver disease) or had missing 154 
endpoint data. Patients who died or underwent liver transplantation before the 155 
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primary endpoint, were also excluded. Ethics approval was waived after review by 156 
local Institutional Review Board. 157 
Data collection 158 
We collected demographic variables, patient characteristics, serological, 159 
histological, laboratory and treatment variables from patient records and local 160 
databases. Laboratory values and predniso(lo)ne dosages were collected at baseline 161 
and after 1, 2, 3, 6, and 12 months of therapy. Original patient data, including 162 
histopathology reports, were used to calculate an AIH diagnostic score for each 163 
patient 19-21. Cumulative predniso(lo)ne dose was calculated using the mean daily 164 
predniso(lo)ne dose each month and then adding up the cumulative dosage per 165 
month to calculate a cumulative dose over time. Data collection was done using a 166 
pre-defined electronic case report form and stored in an online database (Castor 167 
Electronic Data Capture, CIWIT B.V., Amsterdam, The Netherlands).  168 
Outcomes 169 
Our primary outcome was normalization of serum transaminases after 6 170 
months of treatment. We used the upper limit of normal (ULN) from each participating 171 
center to define normalization of transaminases. Secondary endpoints included 172 
biochemical remission (defined as normal serum transaminases and normal serum 173 
IgG), normalization of transaminases at 52 weeks, occurrence of steroid-related side 174 
effects: diabetes mellitus requiring anti-diabetic medication, hypertension requiring 175 
anti-hypertensives and osteopenia and osteoporosis confirmed by bone 176 
densitometry.  177 
Analysis 178 
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We used the starting dose predniso(lo)ne of 0.50 mg/kg/day as advised in the 179 
EASL Clinical Practice Guideline as cut-off point to distinguish the high and low dose 180 
predniso(lo)ne group 3. The low dose group consisted of patients who received a 181 
predniso(lo)ne starting dose of <0.50 mg/kg/day, and the high-dose group were 182 
patients treated with ≥0.50 mg/kg/day. Univariate comparisons of baseline 183 
characteristics between the two groups were made using chi-square, Mann-Whitney 184 
U test or t-test as appropriate. We defined acute severe AS-AIH as a presentation 185 
with an international normalized ratio (INR) ≥1.5 without histological evidence of 186 
cirrhosis 12.  187 
In order to determine the differences in remission between the two groups we 188 
performed logistic regression with normalization of transaminases as dependent 189 
variable. With this method we were able to adjust the primary outcome for potential 190 
confounders. We pre-defined a set of potential confounders (institute, cirrhosis, AS-191 
AIH, age, year of diagnosis, use of maintenance therapy) based on an assumed 192 
association with the primary outcome. Furthermore, significant baseline differences 193 
between groups were included as confounders in the model. All potential 194 
confounders were added to the final regression model. Because of the high 195 
proportion of missing  IgG serum levels after 6 months, we performed a sensitivity 196 
analysis with biochemical remission as dependent variable, this is defined as normal 197 
serum transaminases and normal IgG, which is the definition according to the EASL 198 
Clinical Practice Guideline 3. In addition, we performed a subgroup analysis and 199 
tested for possible effect modification in patients with cirrhosis at baseline and AS-200 
AIH by adding interaction terms (treatment group x variable) in the main model. 201 
Results of multivariable logistic regression are given as odds ratios (ORs) and 95% 202 
confidence intervals (CI). We performed an additional multivariable logistic 203 
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regression analysis to produce institute-specific ORs and consequently a summary 204 
OR for the primary outcome. Heterogeneity among effect sizes was assessed using 205 
the I2 index. An I2 index ≥50% was used to indicate medium-to-high heterogeneity 206 
In addition, we used propensity score matching to compare matched groups of 207 
patients based on baseline disease activity. The propensity score is the probability of 208 
treatment assignment conditional on observed baseline characteristics. We included 209 
biomarkers of disease activity (baseline serum transaminases, bilirubin), use of 210 
maintenance therapy, gender and cirrhosis to calculate a propensity score with 211 
treatment group (high vs. low dose predniso(lo)ne) as dependent variable. Patients 212 
were matched 1:1 using nearest neighbor matching without replacement. P-values 213 
<0.05 were considered statistically significant. Statistical analysis was done with 214 
SPSS version 25 (IBM Corporation, Armonk, NY, USA) and R (R Foundation for 215 
Statistical Computing, Vienna, Austria). 216 
Missing data 217 
We used a multiple imputation model as the primary method to account for 218 
missing data in baseline AST and ALT values. Twenty imputed datasets were 219 
generated using predictive mean matching. Pooled odds ratio’s (OR) from the 220 
imputed datasets were used as final result.    221 
RESULTS  222 
Population characteristics 223 
A total of 880 patients with an established AIH diagnosis were evaluated for 224 
this study. Eventually, 451 patients could be included in our analysis. Main reasons 225 
for exclusion were missing endpoint data and variant syndromes with PBC and PSC 226 
(figure 1). A total of 281 (62.3%) patients were treated with high-dose predniso(lo)ne 227 
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(≥0.50 mg/kg/day) and 170 (37.7%) patients were treated with low-dose 228 
predniso(lo)ne (<0.50 mg/kg/day). Baseline characteristics of the study population 229 
are summarized in table 1. There was a large variation in initial predniso(lo)ne 230 
dosages that were prescribed (supplementary figure 2). Patients in the high-dose 231 
group had significantly higher transaminases and bilirubin at presentation, although 232 
IgG did not differ between the groups. Cirrhosis at index biopsy was present in 25.9% 233 
of the patients in the low-dose group, compared to 15.3% in the high-dose group (p < 234 
0.01). Forty-seven (10.4%) patients presented with acute-severe AIH (AS-AIH) and 235 
were equally distributed between the two arms.  236 
Most of the patients received maintenance therapy (80.2% high-dose group 237 
vs. 83.5% low-dose group, p = 0.39) during their first six months of treatment. 238 
Maintenance therapy consisted mainly of azathioprine (table 2). Other maintenance 239 
therapies included 6-mercaptopurine (3.5%), 6-tioguanine (1.6%), mycofenolate 240 
mofetil (3.1%) and tacrolimus (1.3%). Most patients were still using predniso(lo)ne at 241 
6 months of treatment (87.4% of patients in the high-dose group vs. 83.5% of 242 
patients in the low-dose group (p = 0.32)) and a majority of patients was on a 243 
prednisone dose ≤10 mg at six months (53.2% high dose vs. 58.2% low dose, p = 244 
0.33). Median time to a prednisone dose ≤10 mg was 24 weeks in both groups (p = 245 
0.06). The median cumulative predniso(lo)ne dose of patients with high dose of 246 
predniso(lo)ne was higher (3780 mg) than of those who started on a low dose (2573 247 
mg, p < 0.01).  248 
Treatment response: high vs. low dose predniso(lo)ne 249 
In the high-dose group, 64.7% of patients achieved normalization of 250 
transaminases at six months of treatment compared to 70.5% of patients in the low-251 
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dose group. However, this result was not significant (p = 0.20). Looking at 252 
biochemical remission, incorporating normal IgG at 6 months in patients with 253 
available IgG (268 patients: 86 patients in the low-dose group, 182 patients in the 254 
high-dose group), remission rates remained similar between the two groups: 63.7% 255 
of patients were in remission in the high-dose group compared to 60.5% of patients 256 
in the low-dose group (p = 0.61) (table 3, figure 2). After one year of treatment the 257 
majority of patients in both groups reached normalization of transaminases (76.2% of 258 
patients in the high dose group vs. 77.6% of patients in the low dose group, p = 0.77, 259 
data available for 357 patients). When dividing the patients up into quintiles 260 
according to initial predniso(lo)ne dose, we found that patients with a median initial 261 
predniso(lo)ne dose of 0.31 mg/kg/day still reached normalization of transaminases 262 
at six months in 62.2% of the cases (supplementary figure 1). Cumulative 263 
predniso(lo)ne dose over 6 months and initial predniso(lo)ne dose between patients 264 
with and without normalization of transaminases did not reach the level of statistical 265 
difference (3290 mg vs. 3395 mg, p = 0.40; 0.27 mg/kg/day vs. 0.30 mg/kg/day, p = 266 
0.29). There was no difference in initial starting dose and rates of normalization of 267 
transaminases between patients who received monotherapy predniso(lo)ne (n = 62) 268 
compared to patients who received combination therapy (n = 389) (0.58 mg/kg/day 269 
vs. 0.55 mg/kg/day, p = 0.50; 61.3% vs. 69.4%; p = 0.20).  270 
Treatment response: multivariable analysis 271 
In a multivariable logistic regression model we did not find a significant 272 
difference in chance on normalization of transaminases between the high- and low-273 
dose predniso(lo)ne group. When adjusted for institute, age, gender, ALT and AST at 274 
baseline, year of diagnosis, cirrhosis, use of maintenance therapy and AS-AIH, the 275 
OR for normalization of transaminases for patients who were treated with a high dose 276 
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of predniso(lo)ne was 1.21 (95% CI 0.78 – 1.87, p = 0.38). Of all covariates in the 277 
model, only cirrhosis was significant (p = 0.04). We performed a second analysis, 278 
using institute-specific adjusted ORs to calculate a pooled summary OR. With this 279 
method, the OR for normalization of transaminases was 1.21 (0.67 – 2.19). 280 
Heterogeneity between institutes was low (I2 = 0%) (supplementary figure 3). 281 
The adjusted OR for biochemical remission (n = 268) for patients who were 282 
treated with a high dose of predniso(lo)ne was 1.05 (95% CI 0.59 – 1.86, p = 0.88). 283 
The adjusted OR for normalization of transaminases after one year of treatment was 284 
0.87 (95% CI 0.50 – 1.50, p = 0.61). 285 
Treatment response after propensity score matching 286 
Using propensity score matching we established two matched groups of 108 287 
patients each in the high and low dose predniso(lo)ne groups with equally distributed 288 
disease activity scores. There were no differences in rates of normalization of 289 
transaminases (73.1% vs. 66.7%, p = 0.30) and biochemical remission (62.0% vs. 290 
68.5%, p = 0.45) between high and low dose patients, respectively (table 4). 291 
Treatment response in patients with cirrhosis 292 
Eighty-six patients (19.1%) presented with cirrhosis at baseline. Compared to 293 
non-cirrhotics, patients with cirrhosis were more likely to be men (p = 0.01) and had 294 
lower transaminases at presentation (supplementary table 1). Overall, normalization 295 
of transaminases at six months was lower in patients with cirrhosis vs. non-cirrhotics 296 
(58.1% vs. 70.7%, p = 0.03). Rates between cirrhotics and non-cirrhotics did not 297 
differ in the low dose group (61.4% vs. 65.9%, p = 0.59), but in the high dose group 298 
there was a significant advantage for non-cirrhotic patients (54.8% vs. 73.2%, p = 299 
0.02). There was no interaction between cirrhosis and treatment group (p value for 300 
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interaction = 0.52). The adjusted OR for normalization of transaminases for patients 301 
with cirrhosis treated with a high dose of predniso(lo)ne was 0.96 (0.35 – 2.63, p = 302 
0.93). 303 
Treatment response in AS-AIH 304 
Our cohort consisted of 47 patients who presented with AS-AIH 305 
(supplementary table 2). Most patients were treated with a high dose of 306 
predniso(lo)ne. Rates of normalization of transaminases for AS-AIH patients treated 307 
with a high dose predniso(lo)ne were higher when compared to patients treated with 308 
a low dose of predniso(lo)ne, although not statistically significant (75.9% vs. 61.1%, p 309 
= 0.28). There was no interaction between AS-AIH and treatment group (p value for 310 
interaction = 0.45). The adjusted OR for normalization of transaminases for AS-AIH 311 
treated with a high dose of predniso(lo)ne was 1.50 (0.34 – 6.61, p = 0.59). 312 
Steroid related side effects 313 
Percentage steroid related side effects (diabetes, osteopenia, osteoporosis, 314 
hypertension) did not differ between the low and high dose predniso(lo)ne groups: 315 
18.8% of patients in the low dose group experienced steroid related side effects 316 
during the first year of therapy compared to 21.3% of patients in the high dose group 317 
(p = 0.56). Focusing on each individual steroid related adverse effect, steroid-induced 318 
diabetes and osteoporosis occurred more frequent in the high dose group, but this 319 
did not meet the level of statistical significance (supplementary table 4). 320 
DISCUSSION 321 
AIH patients who receive low dose predniso(lo)ne as induction therapy (<0.50 322 
mg/kg/day) are just as likely to achieve normalization of transaminases and 323 
biochemical remission as patients treated with higher doses of predniso(lo)ne (≥0.50 324 
Downloaded for Anonymous User (n/a) at HUNGARY - Debrecen University from ClinicalKey.com by Elsevier on February 16, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
Prednisone dosage in AIH Pape et al.  
mg/kg/day). The cumulative predniso(lo)ne burden over time was substantially lower 325 
in the <0.50 mg/kg/day group during the first 6 months of therapy (2573 mg versus 326 
3870 mg), although this difference did not result in reduction of steroid related side 327 
effects. 328 
There are no randomized controlled trials that compare various starting doses 329 
predniso(lo)ne in AIH. A recent cohort study compared two different predniso(lo)ne 330 
regimens in 71 AIH patients coming from a single center 22. A group with an initial 30 331 
mg/day predniso(lo)ne dose (0.48 mg/kg) with fast tapering towards 10 mg was 332 
compared with a group that received 40 mg/day (0.62 mg/kg) as initial dose with a 333 
slower tapering regimen. The fast tapering group had lower remission rates 334 
compared to the slow tapering group, but the difference was not statistically 335 
significant (59.4% vs. 79.5%, p = 0.065). We did not observe such a difference 336 
between remission rates between the high and low dose group. Fast tapering of 337 
predniso(lo)ne might result in lower remission rates, however, we were not able to 338 
investigate this in our study.  339 
A logical consequence of higher starting dose is that the cumulative 340 
predniso(lo)ne dosages will likely be higher. Indeed, we found that the exposure to 341 
predniso(lo)ne in the high treatment group was 47% higher. This did not translate to 342 
a higher incidence of adverse events. The retrospective design of our study may 343 
have precluded a detailed assessment as not all adverse events were systematically 344 
documented. Large observational studies in rheumatoid arthritis clearly show a dose 345 
dependent relation between cumulative glucocorticoid dose and steroid-related 346 
adverse events. This holds for severe adverse events such as cardiovascular 347 
mortality and cataract, but also for self-reported adverse events as cushingoid 348 
appearance, sleep disturbance, mycosis, leg edema, acne, weight gain and 349 
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shortness of breath 23-25. Although we did not confirm these results in our AIH 350 
population, it is intuitive to keep cumulative predniso(lo)ne dosage as low as possible 351 
to minimize the risk of steroid-related adverse events.  352 
Eighty-six (19.1%) patients had cirrhosis at presentation, which is in line with 353 
earlier published series 26-28. Cirrhotics had lower baseline ALT, AST and IgG serum 354 
levels, which accords with previous reports 10. Cirrhotics were more likely to receive a 355 
lower dose of predniso(lo)ne (0.49 mg/kg/day vs. 0.60 mg/kg/day for non-cirrhotics). 356 
It is possible that physicians are reluctant to prescribe higher doses of predniso(lo)ne 357 
in cirrhotic patients due to the increased risk of infections associated with 358 
glucocorticoid therapy 29. However, our study shows that lower predniso(lo)ne dosing 359 
in cirrhosis does not impair efficacy when compared to higher dosing (61.4% vs. 360 
54.8%).  361 
Our study comes with a number of limitations. Firstly, due to its retrospective 362 
nature, this study is subject to confounding by indication and selection bias. Only 363 
cases with enough data points were included for our analyses and we had to exclude 364 
a substantial number of patients due to missing data. However, this is the largest 365 
multicenter AIH cohort to date with accurate data during the first six months of 366 
treatment, which allows extrapolation to real world practice. Furthermore, despite the 367 
fact that biochemical disease activity was dissimilar between the two treatment 368 
groups, we managed to provide data on a subset of patients with comparable 369 
biochemical disease activity which showed no difference in rates of normalization of 370 
transaminases or biochemical remission. Secondly, we used normalization of 371 
transaminases as primary endpoint. The recent EASL Clinical Practice Guideline 372 
states that normalization of IgG should be taken into account when defining 373 
biochemical remission of AIH 3. However, we found that IgG as outcome measure is 374 
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not part of routine laboratory testing in all institutions at 6 months after start of 375 
induction therapy, which resulted in a high number of missing IgG data points. We 376 
performed a sensitivity analysis for patients with an available IgG at six months, 377 
which showed no different results than our primary analysis. Although histological 378 
remission is the desired endpoint for every AIH patient, routine liver biopsies in AIH 379 
are not clinical practice and biochemical remission has been accepted as surrogate 380 
endpoint for histological remission in AIH. This is supported by a recent study which 381 
confirmed that biochemical remission predicts remission of histological disease 382 
activity and even regression of fibrosis 30. Thirdly, we did not collect data on liver 383 
transplantation, liver related mortality and morbidity so we are not able to make any 384 
projections about the long-term outcomes of our patients.  385 
Our study established that there is appreciable practice variation among 386 
physicians who treat AIH patients: more than one-third of our cohort was treated with 387 
initial predniso(lo)ne dosages lower than recommended by the EASL Clinical 388 
Practice Guideline 3. Based on our results, we suggest to use an initial starting dose 389 
of <0.50 mg/kg/day in AIH, since this will prevent unnecessary exposure to high 390 
cumulative doses of predniso(lo)ne with potential severe side effects while retaining 391 
efficacy. 392 
In conclusion: the predniso(lo)ne dosage to induce remission in patients with 393 
AIH is less relevant than hitherto assumed. We found that remission was achieved in 394 
the majority of cases regardless of predniso(lo)ne dosage. The important ramification 395 
of our study is that the advised predniso(lo)ne dosages range may be lowered 396 
without attenuating efficacy.  397 
  398 
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Tables & Figures 479 
Table 1:  480 
Baseline characteristics of the study population at time of AIH diagnosis. ALT, 481 
alanine aminotransferase; AS-AIH, acute-severe autoimmune hepatitis; AST, 482 
aspartate aminotransferase; IAIHG, International Autoimmune Hepatitis Group; IgG, 483 
immunoglobulin G, IQR: interquartile range; SD, standard deviation; ULN, upper limit 484 
of normal. * Available for 369 patients. † Available for 449 patients. ‡ Available for 485 
434 patients.  ¶ Available for 381 patients 486 
 487 
  488 
 < 0.50 mg/kg/day 
 (n = 170)  
≥ 0.50 mg/kg/day 
 (n = 281)  
P value 
Female sex, n (%) 125 (73.5%) 213 (75.8%) 0.59 
Age at diagnosis, year (SD) 52.03 (15.35) 49.67 (17.47) 0.13 
Simplified IAIHG score, median 6  7  <0.01 
ALT x ULN, median (IQR)* 7.12 (12.69) 13.44 (21.00) <0.01 
AST x ULN, median (IQR)† 8.52 (17.40) 13.48 (24.27) <0.01 
Bilirubin (µmol/l), median (IQR)‡ 29 (83) 48 (177) 0.01 
IgG (g/l), median (IQR)¶ 20.79 (10.90) 21.60 (13.00) 0.10 
Cirrhosis, n (%) 44 (25.9%) 42 (14.9%) <0.01 
AS-AIH, n (%) 18 (10.6%) 29 (10.3%) 0.93 
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Table 2:  489 
 < 0.50 mg/kg/day 
 (n = 170)  
≥ 0.50 mg/kg/day 
 (n = 281) 
P value 
Predniso(lo)ne dose at start (mg/kg/day), 
median (IQR) 
0.38 (0.15) 0.73 (0.32) <0.01 
Predniso(lo)ne dose at start (mg/day), 
median (IQR) 
30 (11) 50 (20) <0.01 
On predniso(lo)ne at 6 months, n (%)* 146 (87.4%) 237 (90.5%) 0.32 
Predniso(lo)ne dose ≤10 mg at 6 months, 
n (%)* 
85 (58.2%) 126 (53.2%) 0.33 
Predniso(lo)ne dose at 6 months 
(mg/kg/day), median (IQR) 
0.08 (0.09) 0.10 (0.11) <0.01 
Predniso(lo)ne dose at 6 months 
(mg/day), median (IQR)  
7.5 (5.0) 7.5 (5.0) 0.07 
Cumulative predniso(lo)ne dose over 6 
months (mg), median (IQR) 
2573 (1470) 3780 (2450) <0.01 
Predniso(lo)ne dose per day (mg/kg/day), 
median (IQR) 
0.20 (0.09) 0.33 (0.20) <0.01 
On maintenance therapy at 6 months, n 
(%) † 
134 (80.2%) 222 (83.5%) 0.39 
AZA, n (%) 118 (88.1%) 192 (86.5%) 0.67 
6-MP, n (%) 6 (4.5%) 10 (4.5%) 0.99 
6-TG, n (%) 4 (3.0%) 3 (1.4%) 0.28 
MMF, n (%) 3 (2.2%) 11 (5.0%) 0.20 
TAC, n (%) 1 (0.7%) 2 (0.9%) 0.88 
Other, n (%) 2 (1.5%) 4 (1.8%) 0.83 
Treatment characteristics of the study population. 6-MP, 6-mercaptopurine; 6-490 
TG, 6-tioguanine; AZA, azathioprine; IQR, interquartile range; MMF, mycophenolate 491 
mofetil; TAC, tacrolimus. * Available for 383 patients † Available for 433 patients 492 
  493 
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Table 3:  494 
 <0.50 mg/kg/day 
 (n = 170)  
≥0.50 mg/kg/day 
 (n = 281)  
P value 
Normalization of transaminases at 
6 months 
110 (64.7%) 198 (70.5%) 0.20 
 <0.50 mg/kg/day 
 (n = 86)  
≥0.50 mg/kg/day 
 (n = 182)  
P value 
Biochemical remission at 6 months 52 (60.5%) 116 (63.7%) 0.61 
Primary outcome per treatment group. Primary outcome was normalization of 495 
serum transaminases (ALT/AST) after six months of therapy.  A sensitivity analysis 496 
for biochemical remission was done in patients with available IgG at six months. 497 
Biochemical remission is defined as normalization of transaminases and IgG. ALT, 498 
alanine aminotransferase; AST, aspartate aminotransferase; IgG, immunoglobulin G.  499 
  500 
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Table 4 501 
Baseline characteristics and outcomes after propensity score matching. A 502 
propensity score was calculated using baseline transaminases, bilirubin, cirrhosis, 503 
gender and use of maintenance therapy. The matched cohort consists of 216 504 
patients. ALT, alanine aminotransferase; IQR, interquartile range; SD, standard 505 
deviation. * Available for 125 patients 506 
 < 0.50 mg/kg/day 
 (n = 108)  
≥ 0.50 mg/kg/day 
 (n = 108)  
P value 
Female sex, n (%) 83 (76.9%) 82 (75.9%) 0.87 
Age at diagnosis, year (SD) 52.04 (16.13) 50.79 (17.73) 0.59 
Predniso(lo)ne dose at start (mg/kg), 
median (IQR)  
0.39 (0.15) 0.69 (0.32) <0.01 
ALT x ULN, median (IQR) 6.77 (12.89) 7.44 (15.64) 0.28 
AST x ULN, median (IQR) 7.86 (16.30) 8.35 (19.85) 0.58 
Bilirubin (µmol/l), median (IQR) 24.40 (56.7) 34.80 (173.5) 0.10 
IgG (g/l), median (IQR) 20.40 (10.50) 20.80 (15.70) 0.26 
Cirrhosis, n (%) 13 (12.0%) 15 (13.9%) 0.69 
Use of maintenance therapy 93 (86.1%) 90 (83.3%) 0.57 
Normalization of transaminases at 6 
months, n (%) 
72 (66.7%) 79 (73.1%) 0.30 
Biochemical remission at 6 months, n (%)* 37 (68.5%) 44 (62.0%) 0.45 
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Fig 1. Flowchart of all AIH patients included in this study. PBC, primary biliary 
cholangitis; PSC, primary sclerosing cholangitis. 
 
Fig. 2. Primary outcome per treatment group.  A: Rates of normalization of serum 
transaminases. B: Rates of biochemical remission, defined as normalization of serum 
transaminases and serum IgG. IgG, immunoglobulin G. 
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Background 
Guidelines advise a predniso(lo)ne range (0.50–1 mg/kg/day). We performed a 
multicenter study to determine the efficacy of different doses of predniso(lo)ne 
induction therapy in a large European cohort of patients with AIH. 
Findings 
There was no difference in the likelihood of normalization of transaminases between 
patients given an initial high vs. a low dose of predniso(lo)ne. Patients who began 
therapy on a higher dose received more predniso(lo)ne over time than patients 
started on a lower dose. 
Implications for patient care 
The dose of predniso(lo)ne given as induction therapy for patients with AIH is less 
relevant than assumed. An initial predniso(lo)ne dose below 0.50 mg/kg/day 
substantially decreases unnecessary exposure to predniso(lo)ne in patients with AIH. 
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Supplementary table 1: Characteristics of patients with cirrhosis at presentation 
 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; IgG, 
immunoglobulin G; IQR, interquartile range; ULN, upper limit of normal. * Available 
for 369 patients. † Available for 449 patients.  
  
 Cirrhosis 
N = 86 
No Cirrhosis 
N = 365 
P value 
Female sex, n (%) 55 (64%) 283 (77.5%) 0.01 
Age at diagnosis, year (SD) 52.58 (17.97) 50.08 (16.41) 0.21 
Prednisone dose at start (mg/kg), median 
(IQR)  
0.49 (0.41) 0.60 (0.37) 0.01 
ALT x ULN, median (IQR)* 6.87 (9.99) 12.46 (21.15) <0.01 
AST x ULN, median (IQR)† 7.25 (14.07) 12.52 (23.68) <0.01 
Bilirubin (µmol/l), median (IQR) 39.50 (80.50) 40 (168.30) 0.78 
IgG (g/l), median (IQR) 20.67 (10.90) 23.60 (16.70) <0.01 
Normal transaminases at six months, n (%) 50 (58.1%) 258 (70.7%) 0.03 
<0.50 mg/kg/day 27/44 (61.4%) 83/126 (65.9%) 0.59 
≥0.50 mg/kg/day 23/42 (54.8%) 175/239 (73.2%) 0.02 
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Supplementary table 2: Characteristics of patients who presented with acute-severe 
AIH 
AS-AIH is defined as INR ≥ 1.5 at baseline and absence of cirrhosis at index biopsy. 
ALT, alanine aminotransferase; AST, aspartate aminotransferase; IgG, 
immunoglobulin G; IQR, interquartile range; ULN, upper limit of normal *Available for 
369 patients. † Available for 449 patients. ‡ Available for 434 patients.   
 
 
  
 AS-AIH 
N = 47 
Normal AIH 
N = 404 
P value 
Female sex, n (%) 30 (63.8%) 308 (76.2%) 0.06 
Age at diagnosis, year (SD) 47.00 (17.80) 50.97 (16.57) 0.12 
Prednisone dose at start (mg/kg), median 
(IQR)  
0.60 (0.41) 0.57 (0.39) 0.74 
ALT x ULN, median (IQR)* 23.12 (25.67) 8.63 (18.39) <0.01 
AST x ULN, median (IQR)† 19.46 (24.93) 10.07 (20.77) <0.01 
Bilirubin (µmol/l), median (IQR)‡ 193 (262) 31 (115.6) <0.01 
IgG (g/l), median (IQR) 27.45 (15.50) 20.9 (10.8) 0.02 
Normal transaminases at six months, n (%) 33/47 (70.2%) 275/404 (68.1%) 0.77 
<0.50 mg/kg/day 11/18 (61.1%) 99/152 (65.1%) 0.74 
≥0.50 mg/kg/day 22/29 (75.9%) 176/252 (68.1%) 0.50 
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Supplementary table 3: Distribution of patients per institute 
 <0.50 mg/kg/day 
 (N = 170)  
≥0.50 mg/kg/day 
 (N = 281)  
Radboud University Medical Center, The 
Netherlands 
46 24 
Rijnstate Hospital, The Netherlands 8 13 
Leiden University Medical Center, The 
Netherlands 
19 21 
VU University Medical Center, The 
Netherlands 
28 13 
University Medical Center Hamburg-
Eppendorf, Germany 
15 86 
King’s College Hospital, United Kingdom 46 45 
Hannover Medical School, Germany 2 50 
University of Debrecen, Hungary 4 18 
University Hospital of Zurich, Switzerland 2 11 
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Supplementary table 4  
Steroid related side 
effects 
<0.50 mg/kg/day 
(n = 154) 
≥0.50 mg/kg/day 
(n = 235) 
P value 
Total 29 (18.8%) 50 (21.3%) 0.56 
Diabetes 6 (3.9%) 18 (7.7%) 0.13 
Osteopenia 14 (9.1%) 13 (5.5%) 0.18 
Osteoporosis 4 (2.6%) 15 (6.4%) 0.09 
Hypertension 5 (3.2%) 5 (2.1%) 0.50 
Occurrence of steroid-related side effects per treatment group. Data available 
for 389 patients. One patient experienced two events in the ≥0.50 mg/kg/day group 
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Supplementary figure 1. Rates of normalization of transaminases in AIH in 
different treatment groups. Patients were divided into five groups of equal size 
(quintiles) based on initial prednisone dose. Normalization rates per median initial 
prednisone dose are displayed. Sample size per group: 0.31 mg/kg/day: n = 90; 0.46 
mg/kg/day: n = 90; 0.58 mg/kg/day: n = 93; 0.74 mg/kg/day: n = 92; 1.00 mg/kg/day: 
n = 86. The difference between rates is not statistically significant (Chi-square, p = 
0.23). 
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Supplementary figure 2. Frequency distribution of initial predniso(lo)ne 
dosages (mg/kg) used for induction therapy in patients with AIH (n = 451). 
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Supplementary figure 3. Pooled odds ratio (OR) for the primary outcome 
(normalization of transaminases at 6 months of therapy) based on ORs per 
institute. All ORs are adjusted after multivariable logistic regression. 
 
 
 
Downloaded for Anonymous User (n/a) at HUNGARY - Debrecen University from ClinicalKey.com by Elsevier on February 16, 2019.
For personal use only. No other uses without permission. Copyright ©2019. Elsevier Inc. All rights reserved.
